Pfizer (PFE) CEO Albert Bourla believes the U.S. pharmaceutical industry needs to collaborate with China’s, where faster processes have boosted it to 30% of global drug development over the past 10 years, Michael Erman of Reuters reports. “In biopharma, China’s dramatic speed, cost and scale have triggered a shift in the global competitive landscape,” Bourla said, according to Reuters.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Moderately bullish activity in Pfizer with shareslittle changed
- Pfizer’s Tukysa combination shows improved survival in breast cancer trial
- What’s Included in AstraZeneca’s (AZN) ‘Historic’ Drug Discount Deal with Trump?
- AstraZeneca Stock (AZN) Flat despite Incoming Trump Pricing Deal, Virginia Plant Construction
- Moderately bullish activity in Pfizer with shares down 2.04%